Difference between revisions of "Andexanet alfa (Andexxa)"
Jump to navigation
Jump to search
m |
m |
||
| Line 6: | Line 6: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
| + | [[Category:Intravenous medications]] | ||
[[Category:Hematology medications]] | [[Category:Hematology medications]] | ||
[[Category:Hemostasis medications]] | [[Category:Hemostasis medications]] | ||
[[Category:Investigational]] | [[Category:Investigational]] | ||
Revision as of 18:40, 29 October 2017
Mechanism of action
Recombinant inactive FXa, used for specific reversal of DOACs (direct oral anticoagulants).
Preliminary data
- Connolly SJ, Milling TJ Jr, Eikelboom JW, Gibson CM, Curnutte JT, Gold A, Bronson MD, Lu G, Conley PB, Verhamme P, Schmidt J, Middeldorp S, Cohen AT, Beyer-Westendorf J, Albaladejo P, Lopez-Sendon J, Goodman S, Leeds J, Wiens BL, Siegal DM, Zotova E, Meeks B, Nakamya J, Lim WT, Crowther M; ANNEXA-4 Investigators. Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. N Engl J Med. 2016 Sep 22;375(12):1131-41. Epub 2016 Aug 30. link to original article PubMed